Influence of PPARγ on Histone Modifications

To determine the influenceability of the histone modifications H3K4me3 and H3K9ac by PPARy, 50,000 HVT respectively primarily isolated EVT cells were seeded in 500 µL medium (RPMI-1640 + 10% FCS) per chamber of a chamber slide. After growing and adhesion to the slides, the cells were treated with the PPARγ-agonist Ciglitazone (20 mM, Tocris Bioscience, Bristol, UK) [69 (link),70 (link),76 (link)] and the PPARγ antagonist T0070907 (50 mM, Tocris Bioscience, Bristol, UK) or respective control vehicle. After an incubation period of 24 h, immunofluorescence staining was performed. The concentrations of the PPARγ-agonist Ciglitazone and the PPARγ antagonist T0070907, as well as the incubation period were chosen according to the literature published with these chemicals [69 (link),70 (link),71 (link),76 (link),77 (link)].